Vitiligo is clinically characterized by the appearance of non-symptomatic depigmented macules, but the disorder is highly correlated with a wide range of psychiatric disorders and psychological problems. The aim of our study was to investigate serum brain-derived neurotrophic factor (BDNF) and corticotropin releasing hormone (CRH) levels in vitiligo patients and healthy controls in relation to the observed symptoms of depression and anxiety disorders. This study comprised 96 vitiligo patients and 96 healthy controls who filled out the Patient Health Questionnaire-9 (PHQ-9) and Generalized Anxiety Disorder-7 (GAD-7) scales. Serum levels of BDNF and CRH were measured using enzyme-linked immunosorbent assay (ELISA) technique. There was a significant increase of depression and anxiety scores in vitiligo patients as compared with healthy controls (P < 0.05). The serum levels of BDNF were significantly lower in vitiligo patients than in healthy individuals (Z = 4.002; P < 0.001), while the serum levels of CRH were markedly higher in cases than those in controls (Z = 3.764; P < 0.001). The significant positive correlations between serum CRH levels and GAD-7, PHQ-9 scores were observed. However, the aforementioned psychometric scales did not correlate significantly with serum BDNF level. Vitiligo is associated with the depression and is closely linked with lower BDNF levels.

The aim of this research is to determine the characteristics of endothelial factors and the hemostatic system conditions with malignant neoplasms patients, which were exposed to ionizing radiation. Total number of examined people is 223, 153 of them are patients with gastrointestinal tract oncopathology. The article presents the results of the analysis of numerical indicators of endothelial condition and platelet hemostasis of patients, who had cancer. They lived in the regions of Kazakhstan, subjected to contamination of radionuclides as a result of nuclear weapons tests, which took place in this region from 1949 to 1989. These results then were compared to cancer patients and healthy individuals with no radiation risk. The study revealed the presence of higher levels of endothelial dysfunction and following trigger of the hemostatic system in patients with malignant tumors of the gastrointestinal tract. In particular, the defined high degree of endothelial dysfunction include endotheliumdependent vasodilation, content desquamated endothelial cells in peripheral blood and von Willebrand factor. These indicators have a clear correlation with the degree of disorder of studied parameters of the hemostasis, which can cause the development of thrombotic complications.

The purpose of the study was to determine the structure, compliance to antihypertensive pharmacotherapy in patients with arterial hypertension of the third degree in the conditions of Semey and the frequency of achieving target BP.The study included 618 patients with hypertension III degree. The age of patients ranged from 38 to 77 years (mean age -61,2 ± 2,7 years). Among the surveyed men was -353, women -265.Carried out an analysis of medical records and patient survey to determine the structure of antihypertensive therapy, compliance to it and the existing violations preparations reception mode.Was revealed prevalence in the appointment's structure the combinations of antihypertensive drugs (46.0%) and fixed combinations (29.0%). Monotherapy performed more frequently with beta-blockers and calcium channel antagonists.It revealed the greatest compliance to the use of fixed combinations of drugs and most high clinical efficacy of antihypertensive therapy options.Keywords: arterial hypertension -pharmacotherapy -compliance. ТҰЖЫРЫМДАМАЗерттеудің мақсаты -Семей өңіріндегі артериялық гипертензия ІІІ дәрежелі бар науқастарда, антигипертензивті дәрілік терапияның құрылымын, бейілділігін анықтау мақсатты қан қысымын жетуге жиілігі.Зерттеу үшінартериялық гипертензия ІІІ дәрежесімен 618 науқасенгізілген. Науқастардың жасы 38-ден 77 жылға дейін ауытқиды (-61,2 ± 2,7 жыл орташа жасы). Зерттелгендердің арасында ерлер -353, әйелдер -265 болды.Антигипертензивті терапияның және препараттар құрылымын анықтауы, бейілділігі, препараттар қабылдау режимінің бұзылуын тал-дау үшін, медициналық жазбалар мен пациенттердің зерттеуі өткізілді.Тағайындау құрылымында антигипертензивті препараттарының комбинациялары (46,0%) және тіркелген комбинациялар (29,0%) анықталған. Монотерапия неғұрлым бета-блокаторлармен және кальций арналарының антагонистерімен асырылды.Ең жоғары бейілділігі тұрақты дәрілік комбинацияларды қолданған кезде және ең жоғары клиникалық тиімділігі осы топта анықталған. Маңызды сөздер: артериялық гипертензия -фармакотерапия -бейілділігі.

Background Vitiligo is one of the most common hypomelanoses, in which the destruction of functioning melanocytes causes depigmentation of the skin, hair and mucous membranes. The genes encrypting brain-derived neurotrophic factor (BDNF) and corticotropin releasing hormone (CRH) might be the conceivable contributors to the development of vitiligo. This study was aimed at investigation of the serum levels of BDNF and CRH as well as their selected single nucleotide polymorphisms (SNPs) in vitiligo patients in comparison with the healthy controls. Methods The cross-sectional study was carried out between October 2020 and June 2021 in 93 vitiligo patients (age range from 23 to 48 years) and 132 healthy controls (age range from 24 to 52 years). The psychological status of study participants was evaluated using the Generalized Anxiety Disorder-7 (GAD-7) scale. Serum levels of BDNF and CRH were measured with the help of a commercially available sandwich enzyme-linked immunosorbent assay (ELISA) kit. Genotyping for the rs11030094 polymorphism of the BDNF gene and for the rs242924 polymorphism of the corticotropin releasing hormone receptor 1 (CRH-R1) gene was performed by a real-time polymerase chain reaction (PCR). Results There was a significant relationship between the CRH-R1 rs242924 and BDNF rs11030094 polymorphisms and vitiligo. Moreover, serum levels of neurotransmitters differed significantly between vitiligo and control groups and were associated with the CRH-R1 rs242924 and BDNF rs11030094 SNPs. Conclusions Our findings demonstrated the association between CRH-R1 rs242924 and BDNF rs11030094 polymorphisms and vitiligo. Further studies need to be carried out in vitiligo patients to confirm the results observed.

No abstract